Streetbeat News

Products Services

HOOK

HOOKIPA Pharma has presented biomarker and translational data on HB-200 monotherapy at the Society for Immunotherapy of Cancer 2023. The data shows that HB-200 monotherapy induced a significant increase in circulating tumor-specific CD8+ T cells in all evaluable Phase 1 patients with heavily pretreated HPV16+ head and neck cancer. The results reinforce the value proposition of HOOKIPA's arenaviral platform in driving T cell responses necessary for tumor control.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:03 pm

BCRX

CLSD

BioCryst Pharmaceuticals (BCRX) and Clearside Biomedical (CLSD) have entered into a partnership to develop avoralstat for Diabetic Macular Edema (DME) using Clearside's FDA-approved SCS Microinjector. Under the agreement, Clearside will receive a $5 million upfront license fee from BioCryst, with potential for an additional $30 million in clinical and regulatory milestone payments, and up to $47.5 million in post-approval sales-based milestone payments as annual global net sales progress to $2 billion.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:02 pm

PHIO

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) has presented new preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The data highlights the benefits of an INTASYL compound targeting CTLA-4 in conjunction with systemic anti-PD-1 antibody therapy. The combination of the INTASYL compound and anti-PD-1 therapy has shown to enhance the efficacy of anti-PD-1 mAb therapy in vivo, eliciting complete regression of ~40% of treated tumors in a mouse model.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:01 pm

CURLF

TLLTF

TSNDF

VRNOF

Equity research firm Zuanic & Associates has initiated coverage of TILT Holdings (OTC:TLLTF) with an Overweight rating. The firm highlighted the value of TILT's vape hardware franchise and potential synergies between its plant-touching and vape divisions. TILT's cannabis business is gaining momentum in Massachusetts, Ohio, and Pennsylvania. The company's financial stability is also noted, with TILT well-placed to meet its debt maturities until the end of 2025. The firm's bullish case is based on TILT's earnings growth and a reduction in the peer discount.

Portfolio Pulse from Nicolás Jose Rodriguez

November 03, 2023 | 3:53 pm

LVO

PODC

PodcastOne, a subsidiary of LiveOne, has acquired exclusive sales and distribution rights, as well as certain ownership and IP rights, to the true crime podcast, Vigilante. The podcast was named 'Best True Crime Podcast of 2022' and has over 2 million downloads to date. No financial terms of the deal were disclosed.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 3:52 pm

DKNG

DraftKings CEO Jason Robins, in an interview on Bloomberg TV, stated that new entrants into the betting market could potentially expand the overall market. This statement suggests that DraftKings may see increased competition but also potential growth in the industry.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 3:50 pm

AAPL

Apple Inc. (AAPL) has reported a Q4 earnings per share of $1.46, surpassing the estimated $1.31, despite a 1% decrease in revenue to $89.50 billion. The company's net income rose by 11% to $22.96 billion. iPhone sales increased by 2.8%, while Mac and iPad sales declined, with Mac sales dropping by nearly 34%. The stock has seen a 36% increase in value for the year, with a 6% rebound after a 16% dip.

Portfolio Pulse from Zaheer Anwari

November 03, 2023 | 3:48 pm

AZN

AstraZeneca's combination of zibotentan and dapagliflozin has shown significant albuminuria reduction in patients with chronic kidney disease and proteinuria in the ZENITH-CKD Phase IIb trial. The results were presented at the American Society of Nephrology Kidney Week 2023 and simultaneously published in The Lancet. The combination showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR) at 12 weeks compared with dapagliflozin alone. AstraZeneca plans to start Phase III trials in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 3:34 pm

TVTX

Travere Therapeutics has announced late-breaking data from Phase 3 studies of Sparsentan in IgAN and FSGS. The results suggest that Sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure. The drug was well tolerated with a safety profile comparable to the maximally tolerated dose of irbesartan in both Phase 3 studies.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:48 pm

CRON

Cronos Group Inc. has launched its cannabis brand Lord Jones in the Canadian adult-use cannabis market. The brand will focus on THC-focused product innovations, with the first product being Lord Jones Hash Fusions pre-rolls. The product has been extensively researched and sensory tested to deliver a smoother experience featuring bold cannabis flavors. The pre-rolls will be available in Alberta, British Columbia, Manitoba, PEI, Saskatchewan this month and in Ontario, Newfoundland, and New Brunswick by early 2024.

Portfolio Pulse from Jelena Martinovic

November 03, 2023 | 2:41 pm